These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 8601050)

  • 1. Disease-modifying antirheumatic drugs. Potential effects in older patients.
    Gardner G; Furst DE
    Drugs Aging; 1995 Dec; 7(6):420-37. PubMed ID: 8601050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying antirheumatic drugs.
    Conaghan PG; Lehmann T; Brooks P
    Curr Opin Rheumatol; 1997 May; 9(3):183-90. PubMed ID: 9204252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1995 May; 7(3):167-73. PubMed ID: 7612407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.
    Girgis L; Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1994 May; 6(3):252-61. PubMed ID: 7914739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.
    Rains CP; Noble S; Faulds D
    Drugs; 1995 Jul; 50(1):137-56. PubMed ID: 7588084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1996 May; 8(3):176-82. PubMed ID: 8796975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
    N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs.
    Dale J; Alcorn N; Capell H; Madhok R
    Nat Clin Pract Rheumatol; 2007 Aug; 3(8):450-8; quiz, following 478. PubMed ID: 17664952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    McConkey B
    Curr Opin Rheumatol; 1991 Jun; 3(3):348-54. PubMed ID: 1679342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying antirheumatic drugs.
    Li E; Brooks P; Conaghan PG
    Curr Opin Rheumatol; 1998 May; 10(3):159-68. PubMed ID: 9608316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1993 May; 5(3):276-81. PubMed ID: 8099805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs.
    Case JP
    Am J Ther; 2001; 8(2):123-43. PubMed ID: 11304666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
    Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
    Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.